Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 1998

View Archived Issues

One-year trial shows efficacy of lamivudine for treatment for chronic hepatitis B

LY-117018 is fully protective during the later slow phase of bone loss

Selective COX-1 and COX-2 blockade as novel anticancer approach

Company profile: Esperion Therapeutics

OSI receives patent protection for its gene transcription-regulating drugs

Alza: Q1 1998 highlights

Gelatinase inhibitors developed at Sankyo useful for cancer

Paracelsian and Southern Research Institute to develop new anticancer drugs

FDA priority review status granted to Panretin Gel for AIDS-related KS

PathoGenesis completes patient enrollment in phase II TOBI trial

Japanese team presents new antitumor anthracyclines

Solvay describes motilin agonists related to erythromycin

Novel compounds described by Japan Energy for lipid disorders

Antibacterial agent of microbial origin discovered by Sankyo

Sankyo presents new antifungal agents for Candida infections

Medarex begins clinical trials of Bispecific antibody for cancer

FDA grants second orphan drug designation for ImmTher

Celgene cleared to market Thalomid in U.S.

JTV-519 protects heart during prolonged ischemia

FR-167653 attenuates ischemia-reperfusion injury to the lung in rat model

Schering-Plough acquires exclusive worldwide rights to oral ribavirin for HCV

Human vaccination study demonstrates potential of oral and nasal MaxVax

New treatment for male hypogonadism introduced in Germany

Chemokine receptor antagonist NSC-651016 shows potent anti-HIV activity in preclinical studies

PNU-109291, a selective 5-HT1D agonist and potent antimigraine agent

Sanwa Kagaku licenses Bayer antidiabetic agent for Japanese development

FDA accepts license applications for CroTAb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...